SCHEMBL3618682

SCHEMBL3618682

Cc1nc2n(c(=O)c1CCOS(C)(=O)=O)CCS2

nearest known ligand 0.45

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 2/20 0.39
GAA P10253 2/20 0.39
XDH P47989 2/20 0.36
ALDH1A1 P00352 6/20 0.36
LMNA P02545 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HTR6 P50406 1/20 0.35
POLB P06746 3/20 0.35
RAB9A P51151 1/20 0.35
KDM4E B2RXH2 3/20 0.34
TNKS2 Q9H2K2 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10922397 0.79 CYP2C19 (0.44) CYP2C9CYP2C19GAAXDHALDH1A1
SCHEMBL3785984 0.79 GAA (0.47) CYP2C9CYP2C19GAAXDHALDH1A1
Hydrochloric Acid SCHEMBL7291893 0.78 CYP2C19 (0.43) CYP2C9CYP2C19GAAXDHALDH1A1
Bromide SCHEMBL7142006 0.78 CYP2C19 (0.43) CYP2C9CYP2C19GAAXDHALDH1A1
SCHEMBL8804527 0.72 ALDH1A1 (0.52) CYP2C9CYP2C19XDHALDH1A1LMNA
SCHEMBL8474072 0.72 KDM4E (0.33) ALDH1A1LMNAKDM4E
SCHEMBL7318796 0.71 ALDH1A1 (0.51) CYP2C9CYP2C19XDHALDH1A1LMNA
SCHEMBL7318656 0.71 ALDH1A1 (0.51) CYP2C9CYP2C19GAAXDHALDH1A1
SCHEMBL7143254 0.71 HTR2A (0.36)
Bromide SCHEMBL9747692 0.70 ALDH1A1 (0.50) CYP2C9CYP2C19XDHALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8252810-B2 Bicycloamine derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-08-28 US disclosed
US-8252810-B2 Bicycloamine derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-08-28 US disclosed
US-8252810-B2 Bicycloamine derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-08-28 US disclosed
US-20100331310-A1 BICYCLOAMINE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-12-30 US disclosed
US-20100331310-A1 BICYCLOAMINE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-12-30 US disclosed
US-20100331310-A1 BICYCLOAMINE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-12-30 US disclosed
EP-2241567-A1 BICYCLOAMINE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2010-10-20 EP disclosed
US-20090270369-A1 BICYCLOAMINE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-10-29 US disclosed
US-20090270369-A1 BICYCLOAMINE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-10-29 US disclosed
US-20090270369-A1 BICYCLOAMINE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-10-29 US disclosed
WO-2009101917-A1 BICYCLOAMINE DERIVATIVE EISAI R & D MANAGEMENT CO., LTD. (JP) 2009-08-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331310-A1 BICYCLOAMINE DERIVATIVES SCN1B, KCNJ2, KCNH2 CYP2C9 357/4885CYP2C19 359/4885GAA 4207/4885
US-20090270369-A1 BICYCLOAMINE DERIVATIVES SCN1B, KCNJ2, KCNH2 CYP2C9 357/4885CYP2C19 359/4885GAA 4207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.